Pharmacy

Novozymes Biopharma, part of Novozymes A/S, has recently unveiled its enhanced next generation albumin technology, which was developed in collaboration with the University of Oslo, Norway. Built on Novozymes’ original Albufuse platform, the proprietary Albufuse Flex technology has been designed to enable users to adapt and control the pharmacokinetics or their target protein or peptide with retained efficacy, ensuring flexibility and optimal use.

"Novozymes Biopharma is thrilled to introduce Albufuse Flex to the industry. Albumin is a natural and benign carrier molecule, and by having the unique ability to decrease or increase its half-life it will help our customers to develop novel drugs with improved pharmacokinetic properties for a wide range of applications," said Dave Mead, Business Development Director, Novozymes Biopharma.

Further, Prof Inger Sandlie, Group Leader, Norwegian Centre of Excellence for Immune Regulation, added, "The unique Albufuse Flex technology will result in enhanced treatment efficacy, more favourable dosing regimes and improved patient compliance."